Y.AbbasH
(The new advisory panel includes several members with ties to the peptides industry, raising concerns about its impartiality.) After the first day of deliberation, the panel voted in favor of easing restrictions on two popular peptidesBPC-157 and KPVdespite the fact that other FDA scientists have publicly raised concerns about the lack of evidence for these compounds
Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP
Traditionally associated with AD, these proteins are increasingly recognized as part of PD pathology, where KD may hold potential to modulate their effects
Other groups including ICI, (later AstraZeneca), Abbott- Takeda and Hoechst AG, (later Aventis) also developed depot formulations of their respective LH-RH agonists, goserelin, leuprolide, and buserelin consisting of microcapsules or implants in poly (lactide-glycolide) or other polymers administered once a month 3